SLU-PP-332

SLU-PP-332 is a synthetic small molecule designed as a pan-agonist of all three ERR isoforms (α, β, γ). Unlike previous selective ERR ligands, SLU-PP-332's broad-receptor activation is what produces its distinctive exercise-like transcriptomic profile.

SLU-PP-332 emerged from the laboratory of Thomas Burris (Saint Louis University, then Scripps Florida and University of Florida), where the group has been characterizing the estrogen-related receptors (ERRα, ERRβ, ERRγ) as nuclear-receptor regulators of mitochondrial biogenesis and energy metabolism. ERRs are "orphan" nuclear receptors with no known endogenous ligand, but they share extensive transcriptional networks with PGC-1α, the master coactivator of exercise-induced mitochondrial adaptation.

The compound came to broader attention with a 2023 publication (followed by a 2024 Molecular Metabolism paper) showing SLU-PP-332 dosed daily in mice produced increased running endurance, weight loss without reduced food intake, improved insulin sensitivity, and skeletal-muscle gene-expression patterns matching those seen with exercise. The framing as an "exercise mimetic" generated significant interest in research-chemical and biohacker communities.

ERRs drive expression of genes involved in mitochondrial biogenesis, fatty acid oxidation, and oxidative phosphorylation, the same pathways activated by exercise via the PGC-1α coactivator. Direct ERR agonism by SLU-PP-332 is positioned as a way to drive these adaptations without the muscle contraction and metabolic stress that exercise itself requires.^[1]

Mechanistically interesting parallels exist with previous exercise-mimetic candidates, AICAR (AMPK activator) and the now-banned GW501516 (PPARδ agonist), both of which produced striking preclinical results that did not translate cleanly to safe human use. The ERR pathway has a different molecular identity from those programs, but the translational risk pattern is worth keeping in mind.

Pharmacokinetic data for SLU-PP-332 in humans is not published. Preclinical mouse work has used daily intraperitoneal dosing in the milligram-per-kilogram range. Oral bioavailability appears to be acceptable in animal studies but has not been characterized in humans.

The peer-reviewed literature on SLU-PP-332 is summarized below across two tiers: human research (the highest standard), and preclinical / emerging research (animal models and early-stage human work).

This table summarizes commonly discussed claims and how the published evidence weighs in. The aim is clarity, supported claims, claims that look promising but need more data, and claims that outrun the science.

Animal studies have used daily intraperitoneal injection in the mg/kg range. There is no clinical protocol for human use; the compound is not a clinical pharmaceutical product.

SLU-PP-332 is one of the most exciting recent preclinical findings in metabolic / exercise-mimetic biology, the rodent data is striking, the mechanism is mechanistically novel, and the framing has captured significant attention in longevity and performance circles. Practically speaking, for human readers is: this is mouse data. The translational distance from "improves running capacity in mice" to "viable longevity therapeutic in humans" is the same distance that has defeated many earlier exercise-mimetic candidates. Worth tracking as a research direction; not yet supported as a clinical or self-experimentation strategy.